New Therapeutic Strategies and Drug Candidates for Neurodegenerative Diseases: p53 and TNF- Inhibitors, and GLP-1 Receptor Agonists
about
The type 1 TNF receptor and its associated adapter protein, FAN, are required for TNFalpha-induced sickness behavior.Mechanical Stress as the Common Denominator between Chronic Inflammation, Cancer, and Alzheimer's DiseaseMicroglial cell dysregulation in brain aging and neurodegenerationViruses and neurodegenerationRole of redox signaling in neuroinflammation and neurodegenerative diseasesAmyloid β: one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer's diseaseThe entero-insular axis: implications for human metabolism.Potential primary roles of glial cells in the mechanisms of psychiatric disorders.Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injuryImmunity, aging, and geriatric depressionCognitive impairments accompanying rodent mild traumatic brain injury involve p53-dependent neuronal cell death and are ameliorated by the tetrahydrobenzothiazole PFT-α.Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy.Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disordersIncreased Risk of Dementia in Patients With Chronic Obstructive Pulmonary Disease.Blast traumatic brain injury-induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4.Neuroprotective effects of D-Ala(2)GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model.Forebrain neuronal specific ablation of p53 gene provides protection in a cortical ischemic stroke model.Gene expression profiles and protein-protein interaction networks in amyotrophic lateral sclerosis patients with C9orf72 mutationPost-trauma administration of the pifithrin-α oxygen analog improves histological and functional outcomes after experimental traumatic brain injury.GLP-1 receptor plays a critical role in geniposide-induced expression of heme oxygenase-1 in PC12 cells.Protein Drug Targets of Lavandula angustifolia on treatment of Rat Alzheimer's Disease.Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress.Cell-based delivery of glucagon-like peptide-1 using encapsulated mesenchymal stem cells.Molecular Mechanisms behind Free Radical Scavengers Function against Oxidative Stress.Post-traumatic administration of the p53 inactivator pifithrin-α oxygen analogue reduces hippocampal neuronal loss and improves cognitive deficits after experimental traumatic brain injury.TNF-α respecifies human mesenchymal stem cells to a neural fate and promotes migration toward experimental gliomaRelationship of polymorphisms and haplotype in interleukin-16 and adiponectin gene with late-onset Alzheimer's disease risk.Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice.Dopaminergic Neuron-Specific Deletion of p53 Gene Attenuates Methamphetamine Neurotoxicity.Sex Dimorphism Profile of Alzheimer's Disease-Type Pathologies in an APP/PS1 Mouse Model.De Novo Arteriovenous Malformation Growth Secondary to Implantation of Genetically Modified Allogeneic Mesenchymal Stem Cells in the Brain.TNF-α induces human neural progenitor cell survival after oxygen-glucose deprivation by activating the NF-κB pathway.Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner.
P2860
Q24648146-45D4747E-6F38-4C19-9EF9-B6727F61E981Q26781105-C8D3BFB8-43BE-4C5D-97BF-CAD875A9FA01Q26800212-DF42DDDB-6576-4301-8787-4141F06FA73FQ26991740-2BF0DE95-F94E-4E61-83F1-419A809B64D1Q27012569-A88C226B-4B9B-4699-B9BE-D64726F54F50Q28384947-7076D801-72B6-4079-B218-3E2E70DE40D2Q30365939-151084F0-A8A2-49D6-AAA7-3F2DE2DDF650Q30410688-E3AE9B5B-E9BE-453D-B61D-158D6053C961Q34362412-FD4C40B2-A34D-40EA-BBAB-C004B00EDD42Q34997238-CC3D5F46-1C9B-4A80-A3C0-3FA507199E3CQ35060204-187760C2-4AA2-4D43-B811-C53FFD84C5C3Q35748345-38926BD8-C9B9-451F-8638-BF466622C6FCQ36166654-9EF83EC5-123F-433F-8662-94E4A6331A8CQ36194290-D522F836-2F12-4CFF-A525-DFCFEEFC1D05Q36471528-2726B237-9B39-4C98-A4E0-A81F13C6FF07Q36997912-9E26B6AA-4483-456E-8B5D-FF56CBF8C55EQ37137634-155D9F45-BAD4-463A-95BC-835621CF7DD5Q37396365-92EDA959-1F7B-4892-A346-FD799474CF7AQ37541099-770A10EC-EFEB-4B12-A279-0D7E54EB144AQ37728789-2C4B7EC5-4E2E-49BA-9D0F-9F73A748EC24Q38468247-1C9EE016-1F46-4773-A6A5-10811D9DB0B7Q39083326-A368FF3E-D383-4793-AB1D-385C4BC3AE64Q39277278-C6544EAD-E45E-4B49-A2A5-0D84ABC49B8AQ39429504-643DED9D-760E-42EC-BE8E-4D8C76586DBAQ39461208-BB173228-4011-4E33-9CE8-69AF89579AD0Q42107604-4D380EE7-EF2D-41F7-AFD1-42CB1EA026D4Q45331802-A5D8E592-90E2-4073-88DE-86F8782696F5Q47991877-9B687FE1-36C1-406C-8CB4-520351F6A84DQ48362808-52863163-C4F7-4AA5-A473-2F927AC3E84CQ49096980-FD80CF94-8770-4C4C-A96E-61D665395AC2Q52149090-904F53F2-B389-4096-B005-42B99FE7423CQ52721246-51F2CECE-C948-4FC9-A94B-4830E431A85EQ53278044-6CD98218-ECC3-4272-AB99-EED6A03D2CEB
P2860
New Therapeutic Strategies and Drug Candidates for Neurodegenerative Diseases: p53 and TNF- Inhibitors, and GLP-1 Receptor Agonists
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
New Therapeutic Strategies and ...... s, and GLP-1 Receptor Agonists
@ast
New Therapeutic Strategies and ...... s, and GLP-1 Receptor Agonists
@en
New Therapeutic Strategies and ...... s, and GLP-1 Receptor Agonists
@en-gb
New Therapeutic Strategies and ...... s, and GLP-1 Receptor Agonists
@nl
type
label
New Therapeutic Strategies and ...... s, and GLP-1 Receptor Agonists
@ast
New Therapeutic Strategies and ...... s, and GLP-1 Receptor Agonists
@en
New Therapeutic Strategies and ...... s, and GLP-1 Receptor Agonists
@en-gb
New Therapeutic Strategies and ...... s, and GLP-1 Receptor Agonists
@nl
altLabel
New therapeutic strategies and ...... s, and GLP-1 receptor agonists
@en
prefLabel
New Therapeutic Strategies and ...... s, and GLP-1 Receptor Agonists
@ast
New Therapeutic Strategies and ...... s, and GLP-1 Receptor Agonists
@en
New Therapeutic Strategies and ...... s, and GLP-1 Receptor Agonists
@en-gb
New Therapeutic Strategies and ...... s, and GLP-1 Receptor Agonists
@nl
P2093
P3181
P356
P1476
New therapeutic strategies and ...... s, and GLP-1 receptor agonists
@en
P2093
Debomoy K Lahiri
Haim Ovadia
Jack T Rogers
Nigel H Greig
Sic L Chan
Tony Giordano
Tracyann Perry
P304
P3181
P356
10.1196/ANNALS.1332.018
P407
P577
2004-12-01T00:00:00Z